TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia

Drug Category: Array
Conference Category: Array
Lead Author: Cheah C, et al.
Published Date: 19/09/2021
Download Link: /wp-content/uploads/2021/09/Cheah-iwCLL-2021-1701-mono-U2-9.19.21.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top